You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Radiodine refractory Thyroid Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

Recruiting
  • BRAF NP_004324.2:p.V600M
  • +6 more
  • Portland, Oregon
    Providence Portland Medical Center
Aug 17, 2022

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma Trial in Beijing (Anlotinib Hydrochloride

Not yet recruiting
  • Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
  • Anlotinib Hydrochloride Capsule and Penpulimab
  • Beijing, Beijing, China
    YansongLin
Sep 25, 2023

Thyroid Cancer, Thyroid, Refractory Thyroid Cancer Trial in New York (Surveillance Visit)

Recruiting
  • Thyroid Cancer
  • +2 more
  • Surveillance Visit
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 8, 2023

Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer Trial in United States (Trametinib, Dabrafenib, PDR001)

Recruiting
  • Thyroid Cancer
  • +6 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 19, 2023

Locally Advanced or Metastatic Radioiodine-Refractory

Recruiting
  • Thyroid Neoplasms
  • Anlotinib Hydrochloride Capsule
  • Beijing, Beijing, China
  • +2 more
Aug 9, 2023

Human Thyroid and Iodine Resistance

Recruiting
  • Thyroid Cancer
  • Metabolites dosage
  • Toulouse, France
    Institut Claudius regaud IUCT Oncopole
Dec 22, 2022

Efficacy of Lenvatinib in Differentiated Thyroid Cancer

Recruiting
  • Differentiated Thyroid Cancer
  • Gender
  • Rome, Italy
    Regina Elena National Cancer Institute
Mar 16, 2023

Thyroid Cancer Trial in United States (Avutometinib, Defactinib)

Recruiting
  • Thyroid Cancer
  • Basking Ridge, New Jersey
  • +6 more
Aug 17, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

Differentiated Thyroid Cancer Trial in Spain (Cabozantinib)

Not yet recruiting
  • Differentiated Thyroid Cancer
  • Oviedo, Asturias, Spain
  • +9 more
Dec 14, 2022

Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer Trial in New York, Houston (AIC100 CAR T

Recruiting
  • Anaplastic Thyroid Cancer
  • Relapsed/Refractory Poorly Differentiated Thyroid Cancer
  • AIC100 CAR T Cells
  • New York, New York
    Weill Cornell Medical College
Feb 14, 2022

Metastatic Thyroid Cancer Trial in Essen (Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2)

Recruiting
  • Metastatic Thyroid Cancer
  • Trametinib 2 MG [Mekinist]
  • Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
  • Essen, Northrhine-Westphalia, Germany
    Manuel M. Weber
May 17, 2022

Thyroid Tumors Trial in India (Lenvatinib)

Active, not recruiting
  • Thyroid Neoplasms
  • New Delhi, Delhi, India
  • +10 more
Jul 15, 2022

Differentiated Thyroid Cancer Trial in Leiden (rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry)

Recruiting
  • Differentiated Thyroid Cancer
  • rhTSH-stimulated I-124 dosimetry
  • Intra-therapeutic I-131 dosimetry
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Apr 8, 2022

Thyroid Cancer Trial in Ghent (PET/CT scan F18-PSMA-11)

Recruiting
  • Thyroid Cancer
  • PET/CT scan F18-PSMA-11
  • Ghent, Belgium
    University hospital Ghent
Feb 7, 2022

Radioactive Iodine-refractory Differentiated Thyroid Cancer Trial in Beijing (Camrelizumab combination with Apatinib)

Recruiting
  • Radioactive Iodine-refractory Differentiated Thyroid Cancer
  • Camrelizumab combination with Apatinib
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jan 18, 2022

Thyroid Cancer Trial in Peking (Apatinib)

Completed
  • Thyroid Cancer
  • Peking, China
    Peking Union Medical College Hospital
Jan 18, 2022

Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic

Active, not recruiting
  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • +25 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Torrance, California
  • +6 more
Jan 12, 2023

Thyroid Carcinoma Trial in New York (Vemurafenib, serial 124I PET/CT, thyrotropin alpha)

Active, not recruiting
  • Thyroid Carcinoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 28, 2022

Thyroid Cancer Trial in Boston (Nivolumab, Ipilimumab)

Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Feb 18, 2022

Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular Trial in United States (I-124 PET/CT lesion dosimetry,

Recruiting
  • Thyroid Carcinoma
  • +5 more
  • I-124 PET/CT lesion dosimetry
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Mar 3, 2022

Thyroid Cancer Metastatic Trial in France (Lenvatinib + Denosumab)

Recruiting
  • Thyroid Cancer Metastatic
  • Lenvatinib + Denosumab
  • Angers, France
  • +13 more
Mar 14, 2022

Differentiated Thyroid Cancer Trial in Beijing (Donafenib, Placebo)

Terminated
  • Differentiated Thyroid Cancer
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 29, 2021

Thyroid Cancer Trial in Boston, New York, Houston (RAD001)

Completed
Has Results
  • Thyroid Cancer
  • Boston, Massachusetts
  • +3 more
Oct 1, 2021